Mersana Therapeutics Inc
MRSN6.690USD
+0.090+1.36%
Market hours （ET）Quotes delayed by 15 min
833.78MMarket Cap
LossP/E TTM
More Details of Mersana Therapeutics Inc Company
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets.
Company Info
Ticker SymbolMRSN
Company nameMersana Therapeutics Inc
IPO dateJun 28, 2017
CEODr. Martin H. Huber, M.D.
Number of employees102
Security typeOrdinary Share
Fiscal year-endJun 28
Address840 Memorial Dr
CityCAMBRIDGE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02139
Phone16174980020
Websitehttps://www.mersana.com/
Ticker SymbolMRSN
IPO dateJun 28, 2017
CEODr. Martin H. Huber, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Chairman of the Board
Independent Chairman of the Board
23.93K
--
Dr. Timothy B. Lowinger, Ph.D.
Dr. Timothy B. Lowinger, Ph.D.
Senior Vice President, Chief Science and Technology Officer
Senior Vice President, Chief Science and Technology Officer
10.31K
+0.55%
Mr. Brian Deschuytner
Mr. Brian Deschuytner
Chief Financial Officer, Chief Operating Officer, Senior Vice President
Chief Financial Officer, Chief Operating Officer, Senior Vice President
4.86K
+7.10%
Dr. Mohan Bala, Ph.D.
Dr. Mohan Bala, Ph.D.
Senior Vice President, Chief Development Officer
Senior Vice President, Chief Development Officer
2.75K
+0.04%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Independent Director
Independent Director
663.00
--
Ms. Alejandra V. Carvajal, J.D.
Ms. Alejandra V. Carvajal, J.D.
Senior Vice President, Chief Legal Officer
Senior Vice President, Chief Legal Officer
--
--
Dr. Andrew A. F. Hack, M.D., Ph.D.
Dr. Andrew A. F. Hack, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Martin H. Huber, M.D.
Dr. Martin H. Huber, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Anna Protopapas
Ms. Anna Protopapas
Director
Director
--
--
Dr. Willard H. Dere, M.D.
Dr. Willard H. Dere, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Chairman of the Board
Independent Chairman of the Board
23.93K
--
Dr. Timothy B. Lowinger, Ph.D.
Dr. Timothy B. Lowinger, Ph.D.
Senior Vice President, Chief Science and Technology Officer
Senior Vice President, Chief Science and Technology Officer
10.31K
+0.55%
Mr. Brian Deschuytner
Mr. Brian Deschuytner
Chief Financial Officer, Chief Operating Officer, Senior Vice President
Chief Financial Officer, Chief Operating Officer, Senior Vice President
4.86K
+7.10%
Dr. Mohan Bala, Ph.D.
Dr. Mohan Bala, Ph.D.
Senior Vice President, Chief Development Officer
Senior Vice President, Chief Development Officer
2.75K
+0.04%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Independent Director
Independent Director
663.00
--
Ms. Alejandra V. Carvajal, J.D.
Ms. Alejandra V. Carvajal, J.D.
Senior Vice President, Chief Legal Officer
Senior Vice President, Chief Legal Officer
--
--
Revenue Breakdown
FY2025Q1
FY2024
No Data
By RegionUSD
Name
Revenue
Proportion
United States
2.75M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 2
Updated: Wed, Jul 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Nextech Invest, Ltd.
9.68%
Bain Capital Life Sciences Investors, LLC
6.95%
The Vanguard Group, Inc.
6.72%
Schonfeld Strategic Advisors LLC
6.11%
BlackRock Institutional Trust Company, N.A.
5.97%
Other
64.57%
Shareholders
Shareholders
Proportion
Nextech Invest, Ltd.
9.68%
Bain Capital Life Sciences Investors, LLC
6.95%
The Vanguard Group, Inc.
6.72%
Schonfeld Strategic Advisors LLC
6.11%
BlackRock Institutional Trust Company, N.A.
5.97%
Other
64.57%
Shareholder Types
Shareholders
Proportion
Investment Advisor
33.96%
Hedge Fund
16.36%
Investment Advisor/Hedge Fund
13.97%
Venture Capital
5.28%
Individual Investor
1.59%
Research Firm
1.22%
Family Office
0.61%
Bank and Trust
0.09%
Pension Fund
0.07%
Other
26.84%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
344
3.65M
73.32%
-2.99M
2025Q1
381
91.14M
73.20%
-85.10M
2024Q4
376
108.41M
87.04%
-80.71M
2024Q3
381
121.20M
99.04%
-61.95M
2024Q2
378
118.97M
97.46%
-69.30M
2024Q1
377
122.29M
100.13%
-59.89M
2023Q4
366
116.96M
97.07%
-50.97M
2023Q3
372
116.93M
97.32%
-45.36M
2023Q2
374
120.10M
105.19%
-2.78M
2023Q1
353
114.45M
106.31%
-2.65M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Nextech Invest, Ltd.
12.07M
9.68%
--
--
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
8.66M
6.95%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
8.38M
6.72%
+1.32M
+18.71%
Mar 31, 2025
Schonfeld Strategic Advisors LLC
7.61M
6.11%
+5.49M
+259.22%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.44M
5.97%
-865.63K
-10.43%
Mar 31, 2025
AQR Capital Management, LLC
5.14M
4.13%
+5.12M
+27092.58%
Mar 31, 2025
Rock Springs Capital Management LP
3.81M
3.06%
+383.00K
+11.16%
Mar 31, 2025
VR Adviser, LLC
3.57M
2.87%
-6.68M
-65.16%
Mar 31, 2025
SilverArc Capital Management, LLC
3.09M
2.48%
+3.09M
--
Mar 31, 2025
Acadian Asset Management LLC
2.99M
2.4%
+2.99M
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
Fidelity MSCI Health Care Index ETF
0%
Direxion Daily S&P Biotech Bull 3X Shares
0%
iShares Russell 2000 Value ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
Avantis Responsible US Equity ETF
0%
Tema Oncology ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
Proshares Ultra Russell 2000
0%
iShares Morningstar Small-Cap ETF
0%
View more
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Fidelity MSCI Health Care Index ETF
Proportion0%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0%
Avantis Responsible US Equity ETF
Proportion0%
Tema Oncology ETF
Proportion0%
Invesco Nasdaq Biotechnology ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
iShares Morningstar Small-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
